Drugs / Trivalent Inactivated Influenza
Trivalent Inactivated Influenza
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 41 trial | ||||||
| Phase 4 | NCT00396305 | Nov 2006 → Sep 2007 | influenza | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02101749 Comparator | Nov 2013 → Mar 2014 | influenza | Mahidol University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trivalent Inactivated Influenza | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00396305 ↗ |
| Known as | INTANZA | “trivalent inactivated influenza (INTANZA)” NCT02101749 ↗ |
| Known as | VAXIGRIP | “trivalent inactivated influenza (VAXIGRIP)” NCT02101749 ↗ |
| Modality | Vaccine | “influenza vaccine” NCT00396305 ↗ |
| Route | Intramuscular | “All subjects will receive the flu vaccine as an injection in the muscle of the upper arm.” NCT00396305 ↗ |